Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (symbol: EXAS) is a leading molecular diagnostics company based in Madison, Wisconsin. The company specializes in providing innovative cancer screening and diagnostic test products, both in the United States and internationally. One of the company's flagship products is Cologuard, a groundbreaking noninvasive stool-based DNA test that screens for colorectal cancer. This test is integrated into the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.
Exact Sciences is also making significant strides in the field of precision oncology. Their Oncotype DX suite includes tissue-based genomic tests that help estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy for breast and colon cancer patients. Additionally, the OncoExTra test offers comprehensive genomic profiling through a liquid biopsy, providing valuable insights for personalized cancer treatment.
In addition to these established products, Exact Sciences is actively developing new liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. These ongoing projects reflect the company's commitment to advancing cancer diagnostics and improving patient outcomes.
The company's intellectual property portfolio is robust, with exclusive rights protecting its proprietary non-invasive molecular screening technology. This strong IP position underscores Exact Sciences' leadership and innovation in the cancer diagnostics market.
- Headquartered in Madison, Wisconsin
- Specializes in cancer screening and diagnostic tests
- Flagship product: Cologuard, a noninvasive colorectal cancer screening test
- Precision oncology products: Oncotype DX and OncoExTra
- Active development of liquid biopsy tests
- Exclusive intellectual property rights protecting screening technology
For more information on Exact Sciences' noninvasive colon cancer screening test, visit cologuardtest.com.
Exact Sciences Corp. reported first-quarter 2021 revenue of $402.1 million, up 16% from $347.8 million in Q1 2020. Screening revenue grew by 10% to $240.3 million, while Precision Oncology revenue increased by 1% to $129.4 million. COVID-19 testing contributed $32.3 million. The gross margin was 68%, with a non-GAAP gross margin of 73%. The income tax benefit was $242.8 million, leading to a net loss of $31.2 million, improved from $134.6 million in the prior year. The company forecasts full-year revenue between $1,690 million and $1,735 million.
Exact Sciences Corp. (Nasdaq: EXAS) announced management will participate in two upcoming investor conferences in May 2021. The BofA Securities Virtual Healthcare Conference will feature a fireside chat on May 12 at 1:15 p.m. EDT, while the UBS Global Healthcare Virtual Conference will take place on May 25 at 4:00 p.m. EDT. Investors can access the webcasts through the investor relations section of the Exact Sciences website. Exact Sciences focuses on cancer screening and diagnostic tests, aiming to enhance patient care and combat deadly cancers.
Exact Sciences (NASDAQ: EXAS) announced that Cologuard is the most cost-effective colorectal cancer screening option for the Alaska Native population, according to a study published in Mayo Clinic Proceedings. The study demonstrates that Cologuard, a non-invasive stool DNA test, produces the highest number of quality-adjusted life years (QALYs) and significantly reduces colorectal cancer incidence compared to colonoscopy and fecal immunochemical test (FIT). With challenges in screening adherence, Cologuard’s home-use capability presents a promising solution for increasing screening rates.
Exact Sciences Corp. (NASDAQ: EXAS) announced the successful acquisition of Ashion Analytics, enhancing its capabilities in precision oncology. This acquisition includes a CLIA-certified lab and advanced genomic testing options, specifically the GEM ExTra® test. The collaboration with The Translational Genomics Research Institute (TGen) aims to improve advanced cancer diagnostics. This strategic move is projected to bolster patient care and extend Exact Sciences' market leadership in cancer treatment.
Exact Sciences Corp. (Nasdaq: EXAS) will release its first quarter 2021 financial results on May 4, 2021, after the U.S. markets close. Following this, a webcast and conference call will be held at 5 p.m. EDT to discuss the results and business developments. The company focuses on cancer screening and diagnostics, leveraging successful products like Cologuard and Oncotype DX. Exact Sciences aims to enhance patient care through innovative solutions and continued investment in its product pipeline.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in two upcoming virtual investor conferences. The company will hold a fireside chat at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 11:50 a.m. EST, and at the Barclays Global Healthcare Conference on March 9, 2021, at 9:10 a.m. EST.
Investors can access the webcasts via the investor relations section of Exact Sciences' website. The company continues to focus on cancer screening and diagnostic tests to improve patient care.
Exact Sciences Corp. (Nasdaq: EXAS) reported fourth-quarter 2020 revenue of $466.3 million, with full-year revenue reaching $1.49 billion. Q4 screening revenue grew by 9% to $249.7 million, while COVID-19 testing contributed $99.1 million. However, the company faced a net loss of $436.8 million, or $(2.79) per share, compared to a net income of $78.0 million last year. The acquisition of Base Genomics resulted in a $412.6 million research and development charge. Cash reserves stood at $1.84 billion.
Exact Sciences Corp. (Nasdaq: EXAS) announced its acquisition of Ashion Analytics from The Translational Genomics Research Institute (TGen). Ashion, a CLIA-certified sequencing lab, will enhance Exact's precision oncology portfolio, particularly in minimal residual disease (MRD) testing. The acquisition includes a 10-year research collaboration with TGen and City of Hope to develop advanced MRD testing. This partnership aims to expedite bringing innovative genomic solutions to cancer treatment, leveraging Ashion's expertise and TARDIS technology.
Exact Sciences Corp. (Nasdaq: EXAS) is set to release its fourth quarter 2020 financial results on February 16, 2021, after U.S. market close. Management will host a webcast and conference call at 5 p.m. EST to discuss the financial results and business progress. The company is a leading provider of cancer screening and diagnostic tests, with an emphasis on improving patient care through products like Cologuard and Oncotype DX. For further details, visit their official website.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in several upcoming investor conferences in February 2021, inviting investors to join via webcast. Key events include:
- BTIG Virtual MedTech Conference on February 18, 2021 at 10:30 a.m. EST
- Citi Healthcare Services Conference on February 24, 2021 at 9:50 a.m. EST
- SVB Leerink Global Healthcare Conference on February 25, 2021 at 1:40 p.m. EST
Investors can access the webcasts on the company's investor relations webpage.
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
What is Exact Sciences Corp's main business?
What is Cologuard?
Where is Exact Sciences Corp headquartered?
What are Oncotype DX and OncoExTra?
Is Exact Sciences developing any new tests?
What is the significance of Exact Sciences' intellectual property?
Are Exact Sciences' products used internationally?
How does Cologuard work?
What is the purpose of Oncotype DX tests?
Where can more information about Cologuard be found?
